Print

Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression  
10/29/2013 9:30:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that Janssen Research & Development, LLC, on behalf of Janssen Pharmaceuticals, Inc., has completed enrollment of 120 patients in a multicenter, double-blind, Phase 2 study of ADX71149 in adults with major depressive disorder who are also suffering anxiety symptoms.

Help employers find you! Check out all the jobs and post your resume.

//-->